SELLAS Life Sciences Q2 net loss widens on higher expenses

Sellas Life Sciences

11/08/2026 21:13

Overview
US biopharma firm's Q2 net loss widened yr/yr as operating expenses increased
Company ended Q2 with $138.3 mln in cash and cash equivalents
Higher costs driven by manufacturing, clinical, and regulatory activities for lead programs

Result Drivers
R&D SPENDING - Higher research and development expenses mainly due to increased manufacturing, clinical, and regulatory consulting costs for GPS program
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher professional fees and non-cash stock-based compensation

Company press release: ID:nGNX5XSQR0

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$9.61 mln
 
Q2 Loss Per Basic Share
 
$0.05
 
Q2 Operating Expenses
 
$10.63 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $27.50, about 149.1% above its August 10 closing price of $11.04

Reuters Recommended Reads
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 11 - Imunon Q2 net loss widens slightly as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)